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Lithium Chloride Reinforces the Regeneration-Promoting
Effect of Chondroitinase ABC on Rubrospinal Neurons after
Spinal Cord Injury
LEUNG-WAH YICK,1,2 KWOK-FAI SO,1 PIK-TO CHEUNG,2 and WU-TIAN WU1
ABSTRACT
After spinal cord injury, enzymatic digestion of chondroitin sulfate proteoglycans promotes axonal
regeneration of central nervous system neurons across the lesion scar. We examined whether chon-
droitinase ABC (ChABC) promotes the axonal regeneration of rubrospinal tract (RST) neurons fol-
lowing injury to the spinal cord. The effect of a GSK-3 inhibitor, lithium chloride (LiCl), on the
regeneration of axotomized RST neurons was also assessed. Adult rats received a unilateral hemi-
section at the seventh cervical spinal cord segment (C7). Four weeks after different treatments, re-
generation of RST axons across the lesion scar was examined by injection of Fluoro-Gold at spinal
segment T2, and locomotor recovery was studied by a test of forelimb usage. Injured RST axons
did not regenerate spontaneously after spinal cord injury, and intraperitoneal injection of LiCl alone
did not promote the regeneration of RST axons. Administration of ChABC at the lesion site en-
hanced the regeneration of RST axons by 20%. Combined treatment of LiCl together with ChABC
significantly increased the regeneration of RST axons to 42%. Animals receiving combined treat-
ment used both forelimbs together more often than animals that received sham or single treatment.
Immunoblotting and immunohistochemical analysis revealed that LiCl induced the expression of in-
active GSK-3 as well as the upregulation of Bcl-2 in injured RST neurons. These results indicate
that in vivo, LiCl inhibits GSK-3 and reinforces the regeneration-promoting function of ChABC
through a Bcl-2-dependent mechanism. Combined use of LiCl together with ChABC could be a
novel treatment for spinal cord injury.
Key words: axonal regeneration; behavioral analysis; chondroitin sulfate; lithium; rubrospinal tract; spinal
cord injury
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INTRODUCTION
NEURONS IN THE ADULT mammalian spinal cord fail toregenerate axons after injury, resulting in permanent
functional deficits. Modulation of the extrinsic environ-
ment and modeling of the intrinsic response are both em-
ployed as strategies for promoting regeneration and re-
covery of injured central nervous system (CNS) axons.
Specific examples include grafts of peripheral nerves
(Richardson et al., 1982), fetal CNS tissue (Himes et al.,
1994; Diener and Bregman, 1998), or genetically modi-
fied nonneuronal cells (Jin et al., 2002); neutralization of
growth-inhibitory molecules (Caroni and Schwab, 1988;
Schnell and Schwab, 1990; Thallmair et al., 1998); ap-
plication of neurotrophic factors (Kobayashi et al., 1997;
Shibayama et al., 1998); and overexpression of growth-
promoting genes (Mason et al., 2002).
Injury to the spinal cord elicits robust glial reactions
and subsequent formation of gliotic scar (Schwab et al.,
2001; Liesi and Kauppila, 2002). Chondroitin sulfate pro-
teoglycans (CSPGs) are one of the inhibitory components
of the gliotic scar that hinder the regeneration of severed
axons (Dou and Levine, 1994; Bovolenta et al., 1997; 
Fidler et al., 1999). Following spinal cord injury, upreg-
ulation of CSPGs has been found in the gliotic scar sur-
rounding the lesion site (Wang et al., 1997). We and oth-
ers have recently demonstrated that in vivo, enzymatic
degradation of CSPGs at the lesion site can significantly
promote the regeneration of severed axons across the gli-
otic scar in injured brain and spinal cord (Yick et al.,
2000, 2003; Moon et al., 2001; Bradbury et al., 2002).
Lithium has been used for the treatment and prophy-
laxis of mania and depression in humans for almost half
a century. Increasing numbers of studies have indicated
that lithium has neuroprotective effects (Nonaka et al.,
1998; Chen and Chuang, 1999; Wei et al., 2001). How-
ever, the molecular mechanisms underlying the actions
of lithium have not been fully elucidated. Recent studies
have shown that lithium exerts effects via a number of
intracellular signaling pathways, including upregulation
of Bcl-2 and direct inhibition of glycogen synthase ki-
nase-3 (GSK-3) (Chen et al., 1999; Manji et al., 2000).
It has been suggested that lithium-induced Bcl-2 upreg-
ulation plays a crucial role in neuroprotection against glu-
tamate excitotoxicity (Chen and Chuang, 1999). Bcl-2
also supports the intrinsic growth potential of injured ax-
ons (Chierzi et al., 1999; Holm and Isacson, 1999). GSK-
3 is a key downstream target of the PI3-kinase/Akt sig-
naling pathway that regulates apoptosis (Pap and Cooper,
1998; Crowder and Freeman, 2000). Neuronal apoptosis
induced by trophic factor withdrawal is associated with
an increase in GSK-3 activity (Hetman et al., 2000).
A severed rubrospinal tract (RST) can regenerate its
axons under appropriate conditions (e.g. following ap-
plication of neurotrophic factors; Xu and Martin, 1991;
Liu et al., 1999; Jin et al., 2002). The RST is a descend-
ing pathway that has an almost complete contralateral tra-
jectory, allowing unambiguous interpretations of the ax-
onal tracing results (Brown, 1974). In this study, we show
that enzymatic degradation of CSPGs by chondroitinase
ABC (ChABC) can promote the axonal regeneration of
RST after spinal cord injury. Interestingly, we demon-
strate for the first time that the use of lithium chloride
(LiCl), a GSK-3 inhibitor, can markedly reinforce the
regeneration-promoting effect of ChABC on axotomized
RST neurons, resulting in a significant recovery of fore-
limb function.
MATERIALS AND METHODS
Surgical Procedures
Adult 9-week-old Sprague-Dawley rats (200–250 g)
were anesthetized with intraperitoneal injection of keta-
mine (80 mg/kg) and xylazine (8 mg/kg). Under an op-
erating microscope, a dorsal laminectomy was carried out
and the seventh cervical spinal cord segment (C7) was
identified. After opening the dura mater, a right hemi-
section was performed at this level, using a pair of spring
scissors.
Following spinal cord hemisection, animals were di-
vided into four groups. In the first group, animals received
a piece of gelfoam soaked with 0.1 M phosphate-buffered
saline (PBS), placed on top of the lesion site, together with
a daily intraperitoneal injection of 1.0 mL PBS to serve
as the sham control. In the second group, animals received
a gelfoam soaked with PBS, placed on top of the lesion
site, together with daily intraperitoneal injections of 1.0
mL of 85 mg/kg LiCl. In the third group of animals, a
small piece of gelfoam soaked with 10 L of 2.5 units/mL
of Proteus vulgaris ChABC lyase (Seikagaku Corpora-
tion) was placed on top of the lesion site. The animals
also received daily intraperitoneal injections of 1.0 mL
PBS. In the fourth group, animals received a combined
treatment of daily intraperitoneal injections of 85 mg/kg
LiCl together with a piece of gelfoam soaked with 10 L
of 2.5 units/mL of ChABC placed on top of the lesion
site. We have shown that intraperitoneal injection of 85
mg/kg LiCl can protect retinal ganglion cells in a rat glau-
coma model (unpublished observations). In addition,
ChABC at 2.5 units/mL enhances the axonal regrowth of
Clarke’s neurons after spinal cord injury (Yick et al., 2000,
2003). After operation, animals were allowed to survive
for 1 month and were then further subdivided into sub-
groups for either axonal tracing (n  5) or behavioral
analysis (n  4). Two additional groups of animals re-
ceived daily intraperitoneal injection of either PBS or 85
mg/kg LiCl and were used for immunohistochemistry and
Western blot analysis. Animals for immunohistochem-
istry and Western blot were allowed to survive for either
1 or 5 days (n  8 for each time point, n  4 for im-
munohistochemistry, and n  4 for Western blot).
Retrograde Labeling of Regenerated 
RST Neurons
Fluoro-Gold (FG, 6% w/v, Fluorochrome) was used to
label the RST neurons that had regenerated their axons
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across the injury scar and that reentered the caudal spinal
cord. Two days before the end of the postinjury survival
period (1 month), animals were anesthetized with in-
traperitoneal injection of ketamine (80 mg/kg) and xy-
lazine (8 mg/kg). A dorsal laminectomy was then carried
out, and a second thoracic (T2) spinal segment was iden-
tified. FG at a volume of 0.5 L was manually injected
into the right T2 spinal cord using a Hamilton syringe.
Because of the diffusibility of FG in the vicinity of the
injection site and because a relatively large amount of FG
(0.5 L) was used, this procedure actually labeled RST
neurons in both sides.
The RST is a descending pathway in the superficial
dorsolateral white matter of the spinal cord that has al-
most complete (99%) contralateral axonal projection
without spared axons and collateral sprouting (Brown,
1974). Right hemisection at the C7 spinal cord severed
axons from the left red nucleus. Except for rare ipsilat-
eral projections (1% of total RST neurons), injured RST
neurons in the left midbrain with axons regenerating be-
yond the hemisection site to T2 were labeled by FG. Fol-
lowing C7 spinal cord hemisection, the ipsilateral intact
side of the midbrain was used as an internal control.
Tissue Preparation
After the postinjury survival periods, animals were
anesthetized with a lethal dose of ketamine and xylazine
and were perfused intracardially with normal saline, fol-
lowed by 400 mL of fixative containing 4% paraformalde-
hyde in 0.1 M PBS. The brain and spinal cord were re-
moved, postfixed with paraformaldehyde overnight, and
then placed in 30% phosphate-buffered sucrose. Brain and
spinal cord tissues were cut into 30-m sections on a cryo-
stat and mounted onto gelatin-coated slides.
Western Blot and Immunohistochemistry
The effect of LiCl on the phosphorylation state of
GSK-3 and the expression of Bcl-2 in RST neurons was
examined both 1 and 5 days after the surgical operation.
For Western blotting, the primary antibodies used were
the polyclonal anti-p-GSK-3-serine-9 (Cell Signaling
Technology, Beverly, MA), the monoclonal anti-GSK-
3 (Transduction Laboratories, Lexington, KY), and the
monoclonal anti-Bcl-2 (Santa Cruz Biotechnology, Santa
Cruz, CA). The injured and the contralateral intact side
of the red nucleus were rapidly dissected and freshly
frozen at the end of the postoperative survival periods.
Samples of four rats per group were pooled, and the tis-
sue was immediately placed in ice-cold lysis buffer (50
mM Tris-HCl, 150 mM NaCl, 4 mM EDTA, pH 7.4) con-
taining protease inhibitor cocktails (Sigma, St. Louis,
MO), and was homogenized in a Vibra-Cell (Sonic and
Materials, Newtown, CT) homogenizer. The homogenate
was centrifuged at 14,000  g for 40 min at 4°C. The
protein content was assayed by a Coomassie Brilliant
Blue Protein Assay Reagent (Bio-Rad Laboratories,
Richmond, CA). Total protein of 50 g was loaded onto
12.5% polyacrylamide gel with 3.0% stacking gel for
electrophoresis. Proteins were transferred to nitrocellu-
lose membrane (Protran, Schleicher & Schuell, Keene,
NH) at 4°C overnight. The blots were rinsed in Tris-
buffered saline (TBS, pH 7.5) containing 0.1% Tween 20
(TBST) and were then blocked in TBST containing 5%
nonfat milk powder and 2% bovine serum albumin. These
blots were then incubated with the primary antibody for
1 h. The signals were visualized by species-specific
horseradish peroxidase-conjugated secondary antibodies
(Santa Cruz Biotechnology) and a chemiluminescent sub-
strate (Amersham Biosciences, Arlington Heights, IL).
For immunohistochemistry, the primary antibodies
used were the polyclonal anti-p-GSK-3-serine-9 and the
monoclonal anti-Bcl-2. Perfusion-fixed serial cross sec-
tions from the midbrain were preblocked with 2% nor-
mal serum with 0.1% Triton X-100 (Sigma) and then in-
cubated at 4°C for 48 h with either anti-p-GSK-3 Ser9
(1:100) or anti-Bcl-2 (1:200) diluted in Tris-buffered
saline (TBS, pH 7.4) containing 2% normal serum with
0.1% Triton X-100. The signal of the primary antibody
was detected by TRITC-conjugated goat anti-rabbit-IgG
(1:200 diluted in TBS) at room temperature for 1 h. Af-
ter rinsing in TBS, sections were coverslipped in fluo-
rescent mounting medium (Dako, Carpenteria, CA). Con-
trol sections that did not receive the primary antibody
were used to distinguish between specific and nonspe-
cific staining.
Image Analysis, Cell Quantification, 
and Statistics
All images were captured using a SPOT color charge-
coupled device camera (Diagnostic Instruments, Durham,
NC) attached to a Leica fluorescent microscope. For the
quantification of regenerated RST neurons, the number
of FG-labeled RST neurons was counted in every other
section throughout the rostrocaudal extent of the red nu-
cleus (Kobayashi et al., 1997; Liu et al., 1999). Only the
neurons with visible nuclei were counted, to avoid over-
estimation of the number of FG-labeled RST neurons.
Counting was performed blind to the treatment of the an-
imals. The number of FG-labeled RST neurons on the le-
sion side was expressed as a percentage of the total num-
ber of FG-labeled neurons on the contralateral intact side.
For the survival of RST neurons after treatments, sec-
tions were counterstained with neutral red. Only the cells
that were large in size and that possessed a stellate shape
were counted as surviving neurons. Data were compared
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among groups using one-way ANOVA followed by a
Tukey-Kramer multiple comparisons test.
Behavioral Analysis
The use of forelimbs during spontaneous vertical ex-
ploration was examined 1 month after different treatments
as described (Liu et al., 1999), with minor modifications.
Rats were placed for 5 min in a clear Plexiglas cylinder
(15 cm in diameter and 30 cm high) that encourages use
of the forelimbs for vertical exploration. The following
behaviors were scored: independent use of the left (unim-
paired) or right (impaired) forelimbs for contacting the
wall of the cylinder, and simultaneous use of both fore-
limbs to contact the wall of the cylinder. The assessments
were made by two researchers blinded to the treatments.
The vertical exploration behavior was expressed in terms
of percentage use of unimpaired forelimb relative to the
total number of impaired, unimpaired, and both limb use;
percentage use of impaired forelimb relative to the total
number of impaired, unimpaired, and both limb use; and
percentage use of both forelimbs relative to the total num-
ber of impaired, unimpaired, and both limb use. The dif-
ferences between groups were tested by one-way ANOVA
followed by Bonferroni post hoc analysis.
RESULTS
Regeneration of RST after ChABC Treatment
One month after spinal cord hemisection, the regener-
ation of RST axons was studied using the FG retrograde
tracing technique. On the lesioned side of red nucleus,
almost no FG-labeled RST neurons were found in the
sham control animals (2.3  0.9%) 1 month after the op-
eration (Figs. 1 and 2). The few scattered FG-labeled RST
neurons on the lesion side represented those that had ip-
silateral axonal projections without being axotomized.
After local application of 2.5 units/mL ChABC on top of
the spinal cord hemisection site, there were 22.1  4.6%
of the RST neurons on the lesion side labeled by FG. We
did not found any observable differences on the number
of large, stellate-shaped RST neurons on the injured side
between the PBS- and ChABC-treated groups (data not
shown). This result indicates that enzymatic degradation
of CSPGs can promote the axonal regeneration of RST
neurons beyond the lesion site after spinal cord injury.
Effect of LiCl and ChABC on RST Regeneration
After hemisection of the spinal cord, daily intraperi-
toneal injection of 85 g/kg LiCl for 1 month did not al-
ter the percentage of FG-labeled RST neurons as com-
pared with the sham control (p  0.05) (Figs. 1 and 2).
However, combined treatment of application of ChABC
at the lesion site together with daily injection of LiCl sig-
nificantly increased the percentage of FG-labeled RST
neurons to 41.5  6.0% (p  0.001 compared with all
the other treatment groups). No observable differences
were found in the number of large, stellate-shaped RST
neurons on the injured side between different treatment
groups (data not shown).
To examine whether there were FG-labeled axons in
the spinal cord lesion scar, horizontal sections from C7
were cut 1 month after spinal cord hemisection. In all
groups, the spinal cord lesion cavity was filled with scar
tissue without cystic spaces. There were no FG-labeled
axons within the lesion site in either the sham or the LiCl-
treated animals (Fig. 3A,B). In animals treated with
ChABC alone or with LiCl together with ChABC, FG-
labeled axons approximately 100-200 m in length were
found in the lesion scar (Fig. 3C,D). The morphology of
the axons within the scar was similar in these two treat-
ment groups.
Phosphorylation of GSK-3 after LiCl Treatment
Following spinal cord injury, Western blot analysis on
lysates of the lesioned red nucleus revealed that the level
of serine-9-phosphorylated GSK-3 increased 1 and 5
days after LiCl treatment (Fig. 4). The immunoreactivity
of p-GSK-3-serine-9 was barely detectable in the sham
control. The signal of the phosphorylation-independent
antibody, anti-GSK-3, remained stable in all groups.
These results indicate that LiCl leads to the inactivation
of GSK-3 via phosphorylation.
To localize the expression of inactive GSK-3, tissue
sections from the midbrain were immunostained with the
p-GSK-3-serine-9 antibody. Inconsistent with the West-
ern blotting result, intense immunoreactivity of the p-
GSK-3-serine-9 was found on the injured side of the
red nucleus 1 and 5 days after LiCl treatment (Fig. 5).
The p-GSK-3-serine-9 immunoreactivity was mainly
observed in the cytoplasm of the RST neurons. There
were no p-GSK-3-serine-9 immunopositive neurons
found in the intact contralateral side of the red nucleus
in LiCl-treated animals, nor in the injured side of the red
nucleus of the sham control animals. These results indi-
cate that daily intraperitoneal injection of LiCl inactivates
GSK-3 by serine-9 phosphorylation in the lesioned RST
neurons after spinal cord injury.
Expression of Bcl-2 after LiCl Treatment
It has been reported that Bcl-2 protects neurons from
apoptotic cell death as well as enhances axonal regener-
ation after CNS injury (Chen et al., 1997; Yukawa et al.,
2002; Huang et al., 2003). Here we have sought to ex-
LITHIUM AND CHONDROITINASE ABC PROMOTE REGENERATION
935
YICK ET AL.
936
FIG. 1. Photomicrographs of midbrain cross sections showing Fluoro-Gold (FG)–labeled rubrospinal tract (RST) neurons. The
animals received a right hemisection of the spinal cord at C7. The postoperative survival period was 1 month. The RST neurons
in both the control side (right) and the lesion side (left) were retrogradely labeled by injection of FG at T2 spinal cord. In the
sham group (A,B) and the LiCl-treated group (C,D), there are virtually no RST neurons labeled with FG on the lesion side. (E,F)
In chondroitinase ABC-treated animals, few FG-labeled RST neurons are found on the lesion side. (G,H) In animals treated with
LiCl together with chondroitinase ABC, numerous RST neurons are labeled with FG on the left lesion side. Bar  200 m.
amine whether LiCl treatment enhances the expression
of Bcl-2 in RST neurons after injury of the spinal cord.
Immunoblot analysis on lysates of the injured red nucleus
revealed that the expression level of Bcl-2 increased 5
days after LiCl treatment (Fig. 4). The expression of Bcl-
2 was undetectable in the normal and sham control.
After spinal cord hemisection, cryosections from mid-
brains harvested at different time points were immuno-
stained with an antibody against Bcl-2. In the absence of
LiCl, no Bcl-2-expressing neurons were found on both
the contralateral control and injured side of the red nu-
cleus at all the time points examined. Treatment with LiCl
resulted in an intense Bcl-2 immunoreactivity observed
on the injured side of the red nucleus—but not on the in-
tact control side—5 days after the operation (Fig. 6).
These results indicate that Bcl-2 is involved in the addi-
tive regeneration-promoting effect of LiCl on axotomized
RST neurons after treatment with ChABC.
Behavioral Analysis
To examine the recovery of function, a Plexiglas cylin-
der was used to test forelimb use during spontaneous ver-
tical exploration 1 month after different treatments. The
use of forelimbs was expressed by the percentage of wall
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FIG. 2. Percentages of rubrospinal tract (RST) neurons la-
beled with Fluoro-Gold (FG) after different treatments. The an-
imals received a right hemisection of the spinal cord at C7. The
postoperative survival period was 1 month. In the sham and
LiCl-treated animals, virtually no RST neurons are labeled by
FG. Local delivery of chondroitinase ABC (ChABC) increases
the percentage of FG-labeled RST neurons to 22% (sham com-
pared with ChABC ***p  0.001). In animals treated with
LiCl together with ChABC, there are 42% of the RST neurons
labeled with FG (sham compared with LiClChABC ***p 
0.001; ChABC compared with LiClChABC ###p  0.001).
Data are given as percentages of FG-labeled RST neurons on
the lesion side against the number of FG-labeled RST neurons
on the contralateral intact side, mean  SEM.
FIG. 3. Horizontal sections showing the Fluoro-Gold (FG)-
labeled axons within the site of spinal cord hemisection. In the
sham (A) or LiCl-treated animals (B), no FG-labeled axons are
seen within the lesion scar. In the animals treated with chon-
droitinase ABC (C) or LiCl together with chondroitinase ABC
(D), a few FG-labeled axons are observed in the hemisection
site being approximately 100–200 m long (arrows) in the fo-
cal plane. Bar  50 m.
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FIG. 4. Phosphorylation of GSK-3 and upregulation of Bcl-2 after treatment with LiCl. Fifty micrograms of total proteins
from the lesion side of the red nucleus were analyzed by Western blot at 1 and 5 days after spinal cord hemisection. (A) There
was no p-GSK-3-serine 9 immunoreactivity detected in normal (n) and sham (sh) animals. Treatment with LiCl increases the
phosphorylation of GSK-3 at serine-9 by 1 day, persisting up to 5 days, after spinal cord hemisection. (B) The expression level
of phosphorylation-independent GSK-3 was stable throughout the experiment. (C) No Bcl-2 immunoreactivity was detected in
normal and sham animals. LiCl treatment increased the expression of Bcl-2 by 5 days after spinal cord hemisection. (D) -actin
staining was used as an internal control.
FIG. 5. Photomicrographs of midbrain cross sections show-
ing the expression of the phosphorylated serine-9 of GSK-3
in rubrospinal tract neurons on the lesion side. After hemisec-
tion of the C7 spinal cord, the animals received daily in-
traperitoneal injections of LiCl. (A,C) In the sham group, no
p-GSK-3-serine-9 immunoreactive rubrospinal tract neurons
are found by 1 and 5 days after the operation. (B,D) In LiCl-
treated animals, neurons showing positive immunoreactivity
for p-GSK-3-serine-9 are found in the RST nucleus by 1 and
5 days. Bar  50 m.
FIG. 6. Photomicrographs of midbrain cross sections show-
ing the expression of the Bcl-2 in rubrospinal tract neurons on
the lesion side. After hemisection of the C7 spinal cord, the
animals received daily intraperitoneal injections of LiCl. (A,C)
In the sham group, no Bcl-2 immunoreactive RST neurons are
found by 1 and 5 days after the operation. (B,D) In LiCl-treated
animals, neurons showing positive immunoreactivity for Bcl-
2 are found in the RST nucleus by 1 and 5 days. Bar  50 m.
the other treatment groups (17.3  3.8%; sham compared
with LiClChABC, p  0.01; LiCl compared with
LiClChABC, p  0.01; ChABC compared with
LiClChABC, p  0.05). These results demonstrate that
treatment with ChABC, but not LiCl alone, partially pro-
motes the recovery of function after spinal cord injury.
Most interestingly, combined treatment of LiCl together
with ChABC significantly increases the extent of recov-
ery as compared with ChABC treatment alone.
DISCUSSION
Enzymatic degradation of CSPGs promotes the axonal
regeneration of neurons across the lesion scar following
CNS injuries. Lithium has been shown to protect neurons
and enhance axonal regrowth potential via GSK-3 and
Bcl-2 signaling pathways (Bournat et al., 2000; Huang et
al., 2003). In this study, we provide in vivo evidence that
application of ChABC at the lesion site promotes the ax-
onal regeneration of RST neurons after injury of the
spinal cord. Most important, combined treatment of LiCl
together with ChABC further enhances the regeneration
of RST neurons following this injury. This combined
treatment can improve the forelimb function in a vertical
exploration test. Western blot and immunohistochemical
analyses reveal that LiCl treatment induces the expres-
sion of the p-GSK-3-serine-9 as well as the upregula-
tion of Bcl-2 in severed RST neurons. These results in-
dicate that in axotomized RST neurons, lithium reinforces
the regeneration-promoting effect of ChABC via a mech-
anism involving the inactivation of GSK-3 and upreg-
ulation of Bcl-2. Our study confirms previously published
data indicating that enzymatic removal of CSPGs pro-
motes axonal regrowth of injured neurons and that Bcl-
2 is involved in the neuroprotective effect of lithium.
Previous strategies for promoting the axonal regener-
ation of injured RST have been focused on the use of
neurotrophic factors. In a model of chronic spinal cord
injury, continuous administration of BDNF at the mid-
brain reverses massive atrophy and promotes regenera-
tion of rubrospinal axons into a peripheral nerve im-
planted at the lesion site (Kwon et al., 2002). Following
hemisection of the spinal cord, transplants of fibroblasts
genetically modified to express BDNF prevent atrophy,
enhance axonal regeneration of rubrospinal neurons, and
result in partial recovery of forelimb function (Liu et al.,
1999, 2002; Jin et al., 2002). It has been suggested that
neurotrophic factors promote the regeneration of axo-
tomized rubrospinal neurons by stimulating the expres-
sion of GAP-43 and T1-tubulin (Kobayashi et al., 1997;
Fernandes et al., 1999).
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exploration that was initiated by right (impaired) or left
(normal) forelimb alone or by both forelimbs together
(Fig. 7). Normal rats explored the cylinder wall using ei-
ther a single forelimb (about 45%) or both forelimbs to-
gether (about 55%). Animals receiving hemisection at C7
rarely used the forelimb ipsilateral to the injury (sham
group, 7.7  3.0%), leading to asymmetry of forelimb
use. Animals treated with LiCl used both forelimbs
slightly more often, but the difference was not significant
from the sham group (18.1  3.7%; sham compared with
LiCl, p  0.05). In the ChABC-treated group, rats used
both forelimbs more frequently than did the sham group
(29.1  1.9%; sham compared with ChABC, p  0.01),
resulting in more symmetrical forelimb use. However,
combined treatment of LiCl together with ChABC sig-
nificantly promoted the use of both forelimbs as com-
pared with all other treatment groups (38.7  5.2%; sham
compared with LiClChABC, p  0.01; LiCl compared
with LiClChABC, p  0.01; ChABC compared with
LiClChABC, p  0.05). Rats receiving the combined
treatment used both forelimbs together (38.7  5.2%) as
frequently as they used their unimpaired forelimb alone
(44.1  5.9%; both forelimbs compared with unaffected
limb, p  0.05). In addition, the animals receiving the
combined treatment used their impaired forelimb alone
to explore the wall more frequently compared with all
FIG. 7. Behavioral analysis of forelimb function in vertical
exploration test. Normal animals use a single forelimb or both
forelimbs together for vertical exploration. One month after
spinal cord hemisection, animals in the sham and LiCl-treated
groups rarely use their right (impaired) forelimb. Chondroiti-
nase ABC (ChABC)-treated animals use both forelimbs more
frequently for exploration. Animals treated with LiCl together
with ChABC showed significant use of both forelimbs com-
pared to the sham and single treated animals. Data are mean 
SEM. Sham compared with ChABC **p  0.01. ChABC com-
pared with LiClChABC #p  0.05.
We have previously shown that enzymatic degradation
of CSPGs at the injury scar can enhance the regeneration
of the ascending Clarke’s neurons after spinal cord hemi-
section (Yick et al., 2000). Removing the glycosamino-
glycan chains of CSPGs also promotes the regeneration
of severed axons in nigrostriatal and corticospinal tracts
(Moon et al., 2001; Bradbury et al., 2002). In this study,
we demonstrate that CSPGs at the injury scar are im-
portant inhibitory factors for axon regeneration of sev-
ered rubrospinal neurons. Taken together, these in vivo
studies provide evidence that CSPGs are critical in-
hibitory molecules against axonal regeneration in the in-
jured CNS. We are investigating whether multiple treat-
ment with ChABC would be more effective in promoting
axonal regeneration after spinal cord injury.
Although its precise mechanism of action remains un-
known, lithium is a commonly used drug for the treat-
ment of mania and depression (Post et al., 1992). An in
vitro study has demonstrated that lithium supports the cell
survival and axonal regeneration of retinal ganglion neu-
rons (Huang et al., 2003). Long-term exposure to lithium
significantly protects cultured cerebellar, cerebral corti-
cal, and hippocampal neurons against glutamate-induced
apoptotic neuronal death (Nonaka et al., 1998). In a rat
model of Huntington’s disease, subcutaneous adminis-
tration of lithium reduces the size of quinolinic acid-in-
duced lesion and protects striatal neurons from apoptotic
death (Wei et al., 2001). Long-term lithium treatment also
protects cerebellar granule cell neurons from -amyloid
peptide-induced death (Wei et al., 2000). Lithium can
prevent potassium efflux-induced neuronal cell apopto-
sis, with the induction of caspase-3 expression (Li and
El-Mallahk, 2000). Our results show that treatment of
LiCl alone fails to promote the regeneration of severed
RST axons. Interestingly, LiCl seems to potentiate the
neuroregenerative function of ChABC, resulting in an ad-
ditive effect that promotes axonal regeneration of injured
RST neurons. One of the possibilities is that LiCl pro-
tects the injured RST neurons from death so that more
axons can regenerate across the growth-permissive lesion
scar after ChABC treatment. It is also possible that
lithium binds to CSPGs and hyaluronic acid and changes
the water-binding capacity of GAGs, resulting in a syn-
ergistic effect of LiCl and ChABC on axonal regenera-
tion.
We have found that the number of surviving neurons
decreases in the injured red nucleus both in the sham con-
trols and following lithium treatment (data not shown).
This result is different from a previous study, which
showed that axotomized RST neurons survive for 1 year
with regrowth by applying brain-derived neurotrophic
factor (Kwon et al., 2002). It is possible that the dose of
LiCl we used can increase the expression of Bcl-2 but is
not optimal for promoting the survival of injured RST
neurons. We cannot rule out the possibility, too, that the
number of surviving neurons is underestimated because
only large and morphologically normal neurons are
counted, and not the cells with massive atrophy. Further
studies are required to determine whether LiCl can pro-
mote the survival of axotomized RST neurons after spinal
cord injury.
Here, we demonstrate that the number of FG-labeled
RST neurons is significantly increased after the combined
treatment of LiCl together with ChABC. The number of
RST neurons that are labeled for p-GSK-3-serine 9 or
for Bcl-2 is limited. This result indicates that in addition
to inactivation of GSK-3 and upregulation of Bcl-2,
other mechanisms may be involved in the synergistic ef-
fect of LiCl and ChABC.
There is growing evidence that GSK-3 signaling is
involved in neurodegeneration by modulating neuronal
apoptosis. GSK-3 is activated by phosphorylation at
Tyr216 kinase domain and is inactivated through phos-
phorylation of serine-9 (Kaylor and Orr, 2002). The ex-
ecutive phase of apoptosis is associated with a selective
phosphorylation of serine-9 together with dephosphory-
lation of tyrosine-216 in GSK-3 (Bhat et al., 2000; Elya-
man et al., 2002). Lithium is a selective inhibitor of GSK-
3, which may in turn regulate transcriptional factors
such as nuclear factor kappa-B (Bournat et al., 2000) and
cyclic AMP response element binding protein (Grimes
and Jope, 2001). The activity of GSK-3 is negatively
regulated by signal transduction cascades that protect
neurons against apoptosis, including the PI-3 kinase-Akt
pathways (Hetman et al., 2000). By using a neuronal
apoptosis model in neonatal rats, it has been demonstrated
that LiCl can prevent GSK-3–mediated Tau phosphor-
ylation in response to a NMDA receptor antagonist (Elya-
man et al., 2002). Our Western blot and immunohisto-
chemical analyses provide in vivo evidence that after
spinal cord hemisection, LiCl treatment inhibits GSK-3
by phosphorylation at serine-9 in the red nucleus.
In addition to GSK-3 inhibition, it has been recently
demonstrated that lithium regulates the expression of an-
tiapoptotic proteins like Bcl-2. Bcl-2 is an antiapoptotic
gene that inhibits Bax-mediated release of cytochrome c
or apoptosis-inducing factors from mitochondria, thereby
preventing caspase activation of cell death. In a culture
model, lithium increases the expression of Bcl-2 mRNA,
as well as promotes both the survival and axonal regen-
eration of retinal ganglion cells (Huang et al., 2003). In
a rat model of Huntington’s disease, lithium treatment in-
creases Bcl-2 protein levels and suppresses excitotoxin-
induced striatal lesions (Wei et al., 2001). Under gluta-
mate excitotoxicity, long-term treatment of cultured
cerebellar granule cells with lithium upregulates the
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mRNA and protein levels of Bcl-2 remarkably (Chen and
Chuang, 1999). In this study, immunoblotting and im-
munohistochemical analyses reveal that Bcl-2 is upregu-
lated in the injured red nucleus after LiCl treatment. It is
possible that LiCl reinforces the neuroregenerative-pro-
moting effect of ChABC by mediating the upregulation
of Bcl-2 expression in injured RST neurons. However,
further studies are required to examine the temporal re-
lationship between Bcl-2 upregulation and RST axonal
regeneration after spinal cord injury.
In our study, administration of LiCl alone did not pro-
mote RST regeneration, but it enhanced the regeneration-
promoting function of ChABC on injured RST. It has
been demonstrated that the role of lithium on enhancing
neuronal survival may involve inhibition of NMDA re-
ceptors, downregulation of proapoptotic genes such as
p53 and Bax, increased expression of the neuroprotective
protein Bcl-2, and activation of the cell survival kinase
Akt. However, the role of LiCl in the promotion of ax-
onal regeneration is unclear. Bcl-2 plays a key role in
promoting regeneration of injured axons in the CNS
(Chen et al., 1997). Lithium enhances the axonal regen-
eration of retinal ganglion cells through a Bcl-2–depen-
dent mechanism (Huang et al., 2003). Further studies are
required to understand the precise mechanism of lithium-
promoted axonal regeneration in the injured CNS.
On the basis of observations of vertical exploring ac-
tivity with forelimbs in a cylinder, our behavioral result
shows that treatment with ChABC reduces the asymme-
try of forelimb use after injury of the spinal cord. Inter-
estingly, combined treatment of LiCl together with
ChABC further relieves the asymmetry of forelimb use
compared with ChABC treatment alone. Treatment with
LiCl alone does not improve forelimb function. These re-
sults are consistent with our histological data, showing
that the number of regenerating RST neurons is increased
in the animals with the combined treatment compared
with ChABC application alone.
This study provides in vivo evidence that application
of ChABC promotes the axonal regeneration of RST neu-
rons after spinal cord injury. Most interestingly, com-
bined treatment of ChABC together with LiCl results in
an additive effect on promoting RST axonal regenera-
tion. The combined treatment enhances the recovery of
forelimb function compared with a single application of
ChABC alone. Treatment with LiCl inhibits the activity
of GSK-3 and upregulates the expression of Bcl-2 in
axotomized RST neurons. These results indicate that LiCl
reinforces the neuroregeneration-promoting function of
ChABC via inhibiting GSK-3 and upregulating Bcl-2.
To improve the regenerative response after CNS injury,
it will be important to develop intervention that alters the
CSPG components of the glial scar as well as stimulates
the intrinsic regrowth capability of the injured neurons.
Combined use of lithium together with ChABC may be
a novel strategy for the treatment of spinal cord injury.
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